Literature DB >> 16980217

Spondyloarthropathy: disease at the crossroads of immunity.

Oliver FitzGerald1, Iain McInnes.   

Abstract

Up until recently, the prevailing paradigm relating to spondyloarthropathy (SpA) pathogenesis was that they were human leukocyte antigen (HLA)-associated, T-cell-driven autoimmune diseases. This view is now being questioned. Careful studies of well-characterised cohorts of patients with SpA, including detailed analysis of involved tissue, together with clinical trials of targeted treatments, in particular anti-tumour necrosis factor (TNF) therapies, have contributed enormously to both interest in and understanding of disease pathogenesis. In this chapter, our current knowledge and understanding of the relative contributions of the components of the innate and adaptive arms of the immune response to SpA pathogenesis is reviewed. It is clear that both arms of the immune response are involved and inter-dependent in SpA. With continued emphasis on discovery research, including detailed analysis of novel therapeutic interventions, significant additional breakthroughs in SpA are likely to be forthcoming.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980217     DOI: 10.1016/j.berh.2006.06.010

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  4 in total

1.  Mannose-binding lectin 2 gene haplotype analysis in Korean patients with ankylosing spondylitis.

Authors:  Churl Hyun Im; Jinhyun Kim; Yun Jong Lee; Eun Young Lee; Eun Bong Lee; Kyung Sook Park; Yeong Wook Song
Journal:  Rheumatol Int       Date:  2011-05-05       Impact factor: 2.631

2.  Insights into the pathogenesis of axial spondyloarthropathy from network and pathway analysis.

Authors:  Jing Zhao; Jie Chen; Ting-Hong Yang; Petter Holme
Journal:  BMC Syst Biol       Date:  2012-07-16

Review 3.  Profile of certolizumab and its potential in the treatment of psoriatic arthritis.

Authors:  Maria Sole Chimenti; Rosita Saraceno; Andrea Chiricozzi; Alessandro Giunta; Sergio Chimenti; Roberto Perricone
Journal:  Drug Des Devel Ther       Date:  2013-04-15       Impact factor: 4.162

Review 4.  Active axial spondyloarthritis: potential role of certolizumab pegol.

Authors:  Sriya Ranatunga; Anne V Miller
Journal:  Ther Clin Risk Manag       Date:  2014-02-12       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.